Abstract: Laminate or knitted medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble or insoluble silk film or silk sponge, and/or a layer of a knitted silk mesh which was co-knitted with one, two or three layers of silk or non-silk fabric.

Abstract: An aqueous contact lens solution comprising less than 100 ppm of a tertiary amine oxide of general formula wherein R1 is a C8-C18alkyl, and R2 and R3 are independently selected from a C1-C4alkyl or C1-C4hydroxyalkyl, and an antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds, hydrogen peroxide or a stabilized form of peroxide and any one mixture thereof. The solution has no anionic surfactant or less than 30 ppm of anionic surfactant. The invention is also directed to the use of the solution to clean and disinfect contact lenses, and in particular, soft, silicone, hydrogel contact lenses.

Abstract: Ophthalmic compositions that comprise 0.1 ppm to 50 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 2 wt. % of an anionic biopolymer; and 0.01 wt. % to 2 wt. % of an amphoteric surfactant of general formula I wherein R1 is R or —(CH2)n—NHC(O)R, wherein R is a C8-C30alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R2 and R3 are each independently selected from C1-C4alkyl; R4 is a C2-C8alkylene optionally substituted with hydroxyl; and Y is CO2? or SO3. The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Abstract: Laminate or knitted medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble or insoluble silk film or silk sponge, and/or a layer of a knitted silk mesh which was co-knitted with one, two or three layers of silk or non-silk fabric.

Abstract: An ophthalmic composition comprising 0.5 ppm to 3 ppm of poly(hexamethylene biguanide), and 0.002 wt. % to 0.03 wt. % of hyaluronic acid. The weight ratio of hyaluronic acid to poly(hexamethylene biguanide) in the composition is from 45:1 to 120:1. The invention is also directed to a method of cleaning, disinfecting or packaging contact lenses with the composition, or to a method of rewetting contact lenses with the composition.

Abstract: Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 0.01 ppm to 3 ppm poly(hexamethylene biguanide); 1 ppm to 10 ppm ?-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl)ammonium chloride; and 0.1% w/v to 2% w/v of one or more boron buffering compounds.

Abstract: Embodiments of the present disclosure may empower companies to financially leverage the connected communities of their employees to drive company revenues, brand awareness and product adoption. A marketing engine may act as an engagement catalyst for these employees. Employees have personal spheres of influence in their socially connected communities that can be utilized by their employer's marketing initiatives. One-to-one marketing efforts by the employees are extremely powerful and impactful when compared to broader advertising messages. The marketing engine may engage employees in the promotion of products and services offered by their company through social media campaigns. In return, the company may reward those employees for their involvement within their connected communities through a series of rewards. The employees may participate in these micro-marketing activities without the company knowing which employees are participating and the extent of that participation.

Abstract: An ophthalmic composition comprising one or more antimicrobial components and a dipeptide. The dipeptide comprises a glycine moiety and another amino acid moiety other than glycine. The ophthalmic compositions include contact lens care solutions for cleaning and disinfecting contact lenses.

Abstract: Sterilized aqueous solution comprising 0.04% to 0.8% by weight hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and one or more buffer components selected from the group consisting of boric acid, sodium borate and sodium dihydrogen phosphate. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 4% to 18% by weight of sodium chloride and a pH from 6.4 to 7.2. The solution is also filtered through a filter medium that has an average pore size of 0.25 ?m or less to provide a sterilized high salt, hyaluronic acid solution.

Abstract: Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 0.01 ppm to 3 ppm poly(hexamethylene biguanide); 1 ppm to 10 ppm ?-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl)ammonium chloride; and 0.1% w/v to 2% w/v of one or more boron buffering compounds.

Abstract: Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 1.0 ppm to 8.5 ppm alexidine, and 0.1% w/v to 2% w/v of one or more boron buffering compounds.

Abstract: Sterilized aqueous solution comprising 0.04% to 0.8% by weight hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and one or more buffer components selected from the group consisting of boric acid, sodium borate and sodium dihydrogen phosphate. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 4% to 18% by weight of sodium chloride and a pH from 6.4 to 7.2. The solution is also filtered through a filter medium that has an average pore size of 0.25 ?m or less to provide a sterilized high salt, hyaluronic acid solution.

Abstract: Ophthalmic compositions that comprise 0.5 ppm to 15 ppm ?-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl) ammonium chloride; 0.005 wt. % to 0.05 wt. % hyaluronic acid; citrate, citric acid or a mixture thereof; and 0.01 wt. % to 0.8 wt. % of an amphoteric surfactant of general formula I wherein R1 is R or —(CH2)n-NHC(O)R, wherein R is a C8-C30alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R2 and R3 are each independently selected from the group consisting of hydrogen and C1-C4alkyl; R4 is a C2-C8alkylene optionally substituted with hydroxyl; and Y is CO2? or SO3?. The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Abstract: A process for sterilizing a solution comprising hyaluronic acid. The process comprises providing an aqueous solution of hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and the concentration of the hyaluronic acid is from 0.04% to 0.8% by weight. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 3% to 30% by weight. Once the aqueous, high salt, hyaluronic acid solution is prepared the solution is maintained at a temperature from 40° C. to 80° C. for at least 1 hour and not longer than six days. Following the heat treatment step, the aqueous solution is filtered through a sterilization filter medium to provide a sterilized high salt, hyaluronic acid solution.

Abstract: Ophthalmic composition comprising one or more polyglycines selected from the group consisting of diglycine, triglycine, tetraglycine and pentaglycine, or the salts of each thereof and one or more boron buffering compounds. The ophthalmic composition will have an osmolality of from 200 mOsmol/kg to 420 mOsmol/kg.

Abstract: Ophthalmic compositions that comprise 0.1 ppm to 10 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 0.15 wt. % of hyaluronic acid; and 0.01 wt. % to 1.0 wt. % of an amphoteric surfactant of general formula I wherein R1 is R or —(CH2)n—NHC(O)R, wherein R is a C8-C16alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R2 and R3 are each independently selected from methyl, ethyl, propyl or iso-propyl; and R4 is a C2-C8alkylene optionally substituted with hydroxyl. The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Abstract: A process for sterilizing a solution comprising hyaluronic acid. The process comprises providing an aqueous solution of hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and the concentration of the hyaluronic acid is from 0.04% to 0.8% by weight. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 3% to 30% by weight. Once the aqueous, high salt, hyaluronic acid solution is prepared the solution is maintained at a temperature from 40° C. to 80° C. for at least 1 hour and not longer than six days. Following the heat treatment step, the aqueous solution is filtered through a sterilization filter medium to provide a sterilized high salt, hyaluronic acid solution.

Abstract: Compositions comprise a polymer having units of an amino sugar, a polyol other than sorbitol, and boric acid, a salt thereof, or a combination thereof. Such compositions remain for an extended period in the eye and can be used for relief, treatment, or control of a condition of dry eye or discomfort resulting therefrom.

Abstract: An aqueous solution for cleaning and disinfecting a contact lens comprising 0.5 ppm to 5 ppm of 1,1?-hexamethylene-bis[5-(2-ethylhexyl)biguanide; 0.5 ppm to 3 ppm ?-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl)ammonium chloride; 0.005 wt. % to 0.04 wt. % hyaluronic acid; a boric acid/borate buffer; and a nonionic surfactant selected from poloxamer, poloxamine or any combination thereof.

Abstract: A method of retaining hyaluronic acid on a surface of a contact lens. The method comprises providing a contact lens care solution comprising; 0.005 wt. % to 0.05 wt. % of hyaluronic acid in a borate containing buffer, and 0.01 wt. % to 1.0 wt. % of an amphoteric surfactant of general formula I wherein R? is a C8-C16alkyl optionally substituted with hydroxyl; R2 and R3 are each independently selected from methyl, ethyl, propyl or iso-propyl; and R4 is a C2-C8alkylene optionally substituted with hydroxyl; and soaking the contact lens in the contact lens care solution for at least two hours prior to placement of the contact lens in an eye.